Bone Biologics (BBLG) Cash from Operations (2012 - 2025)
Bone Biologics (BBLG) reported Cash from Operations of 700000.0 for Q4 2025, up 48.28% year-over-year from 472073.11 in Q4 2024, and down 16.67% quarter-over-quarter from 600000.0 in Q3 2025.
Bone Biologics (BBLG) Cash from Operations (2012 - 2025) Analysis & Trends
Bone Biologics (BBLG) has 14 years of Cash from Operations data on file, last reported at 700000.0 in Q4 2025.
- Cash from Operations for Q4 2025 came in at 700000.0, up 48.28% year-over-year; the trailing twelve-month figure through Dec 2025 was 2700000.0 (up 34.54% YoY), and the FY2025 annual result was 2700000.0, up 34.54% from the prior year.
- Cash from Operations eased to 700000.0 in Q4 2025 per BBLG's latest filing, from 600000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 127983.0 in Q1 2021 and troughed at 3632673.0 in Q2 2023.
- A 5-year average of 1058816.9 and a median of 780389.5 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations sank 944.03% in 2022, then surged 77.61% in 2024.
- A 5-year view of Cash from Operations shows it stood at 186852.0 in 2021, then slumped by 944.03% to 1950791.0 in 2022, then retreated by 3.45% to 2018015.0 in 2023, then surged by 32.93% to 1353497.0 in 2024, then soared by 48.28% to 700000.0 in 2025.
- Business Quant data shows BBLG's Cash from Operations at 700000.0 in Q4 2025, 600000.0 in Q3 2025, and 500000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | -700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -700,000.00 |
| Dec 31, 2025 | -700,000.00 |
| Sep 30, 2025 | -600,000.00 |
| Sep 30, 2025 | -600,000.00 |
| Jun 30, 2025 | -500,000.00 |
| Jun 30, 2025 | -500,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Dec 31, 2024 | -1.35 Mn |
| Dec 31, 2024 | -1.35 Mn |
| Sep 30, 2024 | -572,162.00 |
| Sep 30, 2024 | -572,162.00 |
| Jun 30, 2024 | -895,865.00 |
| Jun 30, 2024 | -895,865.00 |
| Mar 31, 2024 | -1.30 Mn |
| Mar 31, 2024 | -1.30 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Sep 30, 2023 | -2.56 Mn |
| Sep 30, 2023 | -2.56 Mn |